Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vertex Pharmaceuticals

429.60
-5.2200-1.20%
Post-market: 429.600.00000.00%19:58 EDT
Volume:2.94M
Turnover:1.26B
Market Cap:110.32B
PE:-111.83
High:432.14
Open:430.17
Low:423.40
Close:434.82
Loading ...

Jim Cramer on Vertex Pharmaceuticals (VRTX): “Revolutionary Pain Drug on the Horizon!”

Insider Monkey
·
31 Mar

Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
31 Mar

Vertex Pharmaceuticals Inc : Bofa Global Research Raises Price Objective to $567 From $555

THOMSON REUTERS
·
31 Mar

Vertex Pharmaceuticals Ends VX-264 Study in Diabetes After Failing to Meet Efficacy Endpoint

MT Newswires Live
·
31 Mar

Vertex Pharmaceuticals’ Journavx: Strong Demand and Positive Outlook Drive Buy Rating

TIPRANKS
·
31 Mar

Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

ACCESS Newswire
·
31 Mar

Vertex Minerals Starts Trading on US OTCQB Market; Shares Fall 4%

MT Newswires Live
·
31 Mar

Vertex Pharmaceuticals (NasdaqGS:VRTX) Advances Diabetes Portfolio Despite 2% Decline in Share Price

Simply Wall St.
·
30 Mar

Vertex Pharmaceuticals: Strategic Advancements and Promising Market Potential Drive Buy Rating

TIPRANKS
·
29 Mar

Is Vertex Pharmaceuticals (VRTX) The Most Expensive Stock Insiders Are Dumping In March?

Insider Monkey
·
29 Mar

Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
29 Mar

Vertex Pharmaceuticals pursuing research-stage T1Dd programs

TIPRANKS
·
29 Mar

BRIEF-Vertex Pharmaceuticals Inc - Expects $400 Million Impairment Charge For VX-264 - SEC Filing

Reuters
·
29 Mar

Vertex Pharmaceuticals Inc - Expects $400 Million Impairment Charge for Vx-264 - SEC Filing

THOMSON REUTERS
·
29 Mar

BRIEF-Vertex Announces Program Updates For Type 1 Diabetes Portfolio

Reuters
·
29 Mar

Vertex Announces Program Updates for Type 1 Diabetes Portfolio

THOMSON REUTERS
·
29 Mar

Vertex Pharmaceuticals Inc - Efficacy Data Are Not Supportive of Further Clinical Advancement of Vx-264

THOMSON REUTERS
·
29 Mar

Vertex Pharmaceuticals Inc - Expects Global Regulatory Submissions for Zimislecel in 2026

THOMSON REUTERS
·
29 Mar

IHI to Sell Construction Materials Business to Vertex to Focus on Growth Areas

MT Newswires Live
·
28 Mar

Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors

Zacks
·
28 Mar